Morning Star Fair Value Estimate 1.40, page-2

i follow space carefully

AC8 remains best exposure - significantly lower market cap than CAN

catalyst will be announcements on import / export which will allow the Canopy Growth products into australia and able to be sold under SAS scheme

This will propel sector and stock for those positioned but AC8 has the platform right via the medical outreach program that will facilitate take up

sales q1 next year possible, stock will be 50% higher i suspect

no idea in when pullback from last weeks highs will end but this is key name in sector